MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Company Overview - MediWound Ltd. is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair, specializing in the development, production, and commercialization of innovative biologics that enhance existing standards of care while reducing healthcare costs and unnecessary surgeries [3][4]. Upcoming Events - The CEO of MediWound, Ofer Gonen, will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, at 8:00 AM ET [1]. - A webcast link for the fireside chat will be available on MediWound's website, and the management team will also host one-on-one meetings during the conference [2]. Product Development - MediWound's first drug, NexoBrid, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for surgical interventions [4]. - The company is advancing EscharEx, a promising candidate currently in Phase III development for the debridement of chronic wounds, which has shown distinct advantages over existing treatments in Phase II clinical trials [4].